Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS Q61K lung cancer predicted - resistant RMC-4550 Preclinical - Cell culture Actionable In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cells harboring KRAS Q61K in 3D culture (PMID: 30104724). 30104724
KRAS Q61K non-small cell lung carcinoma sensitive PI3K Inhibitor (Pan) XL147 Preclinical - Cell line xenograft Actionable In a preclinical study, XL147 inhibited tumor growth and vascularization in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K (PMID: 25637314). 25637314
KRAS Q61K non-small cell lung carcinoma sensitive PI3K Inhibitor (Pan) Carboplatin + XL147 Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of XL147 and Paraplatin (carboplatin) inhibited tumor growth and angiogenesis in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K, with increased efficacy compared to either agent alone (PMID: 25637314). 25637314
KRAS Q61K gastric adenocarcinoma predicted - resistant RMC-4550 Preclinical - Cell culture Actionable In a preclinical study, RMC-4550 did not inhibit growth of gastric adenocarcinoma cells harboring KRAS Q61K in 3D culture (PMID: 30104724). 30104724
KRAS Q61K lung adenocarcinoma decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Binimetinib Preclinical - Cell culture Actionable In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS Q61K lung adenocarcinoma decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710). 27422710
KRAS Q61K non-small cell lung carcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor BI-847325 Preclinical - Cell line xenograft Actionable In a preclinical study, BI-847325 inhibited MEK phosphorylation and proliferation and disrupted cell cycle progression in a non-small cell lung cancer cell line harboring KRAS Q61K in culture, and induced tumor stasis or regression in KRAS Q61K mutant non-small cell lung cancer cell line xenograft models (PMID: 27496137). 27496137
Clinical Trial Phase Therapies Title Recruitment Status